Literature DB >> 29259071

Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer.

Charlotte Manogue1, Elisa Ledet1, A Kumar Guddati2, Brian Lewis1,2, Oliver Sartor3,2.   

Abstract

Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies. © AlphaMed Press 2017.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29259071      PMCID： PMC5905692          DOI： 10.1634/theoncologist.2017-0450

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  8 in total

1.  Fluorinated pyrimidines, a new class of tumour-inhibitory compounds.

Authors:  C HEIDELBERGER; N K CHAUDHURI; P DANNEBERG; D MOOREN; L GRIESBACH; R DUSCHINSKY; R J SCHNITZER; E PLEVEN; J SCHEINER
Journal:  Nature       Date:  1957-03-30       Impact factor: 49.962

2.  Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.

Authors:  Gregory P Swanson; James Faulkner; Stephen R Smalley; Mark J Noble; Ronald L Stephens; Timothy J O'Rourke; Geoffrey R Weiss; Donald P Quick; Ian M Thompson; E David Crawford
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

3.  5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).

Authors:  J D Berlin; K J Propert; D Trump; G Wilding; G Hudes; J Glick; P Burch; A Keller; P Loehrer
Journal:  Am J Clin Oncol       Date:  1998-04       Impact factor: 2.339

4.  Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.

Authors:  Jose D Murga; Sameer M Moorji; Amy Q Han; Wells W Magargal; Vincent A DiPippo; William C Olson
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

5.  Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.

Authors:  Veronica Yao; Clifford E Berkman; Joseph K Choi; Denise S O'Keefe; Dean J Bacich
Journal:  Prostate       Date:  2010-02-15       Impact factor: 4.104

Review 6.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

7.  Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.

Authors:  A Bex; T Otto; G Lümmen; H Rübben
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

8.  Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.

Authors:  J G Park; J M Collins; A F Gazdar; C J Allegra; S M Steinberg; R F Greene; B S Kramer
Journal:  J Natl Cancer Inst       Date:  1988-12-07       Impact factor: 13.506
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.